![]()
|
|
||||||||
J. Biol. Chem., Vol. 275, Issue 36, 28053-28062, September 8, 2000
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
From the § Department of Biological Chemistry , the
For the type I cGMP-dependent protein
kinases (cGKI
The Amino-terminal Cyclic Nucleotide Binding Site of the Type
II cGMP-dependent Protein Kinase Is Essential for Full
Cyclic Nucleotide-dependent Activation*
and
Neuroscience Graduate Program, and the ¶ Mental
Health Research Institute, University of Michigan,
Ann Arbor, Michigan 48104
and cGKI
), a high affinity interaction exists
between the C2 amino group of cGMP and the hydroxyl side chain of a
threonine conserved in most cGMP binding sites. To examine the effect
of this interaction on ligand binding and kinase activation in the type
II isozyme of cGMP-dependent protein kinase (cGKII),
alanine was substituted for the conserved threonine or serine. cGKII
was found to require the C2 amino group of cGMP and its cognate serine
or threonine hydroxyl for efficient cGMP activation. Of the two binding
sites, disruption of cGMP-specific binding in the
NH2-terminal binding site had the greatest effect on
cGMP-dependent kinase activation, like cGKI. However,
ligand dissociation studies showed that the location of the rapid and
slow dissociation sites of cGKII was reversed relative to cGKI. Another
set of mutations that prevented cyclic nucleotide binding demonstrated
the necessity of the NH2-terminal, rapid dissociation
binding site for cyclic nucleotide-dependent activation of
cGKII. These findings suggest distinct mechanisms of activation for
cGKII and cGKI isoforms. Because cGKII mediates the effects of
heat-stable enterotoxins via the cystic fibrosis transmembrane
regulator Cl
channel, these findings define a structural
target for drug design.
*
This work was supported by National Institutes of Heath
Grant GM50791.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
To whom correspondence should be addressed: Neuroscience
Laboratories Bldg., 1103 E. Huron St., University of Michigan, Ann Arbor, MI 48104-1687. Tel.: 734-647-3172; Fax: 734-936-2690; E-mail: muhler@umich.edu.
This article has been cited by other articles:
![]() |
M. E. Wall, S. H. Francis, J. D. Corbin, K. Grimes, R. Richie-Jannetta, J. Kotera, B. A. Macdonald, R. R. Gibson, and J. Trewhella Mechanisms associated with cGMP binding and activation of cGMP-dependent protein kinase PNAS, March 4, 2003; 100(5): 2380 - 2385. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Taylor, R. Ahmed, M. Begley, and M. D. Uhler Autoinhibition and Isoform-specific Dominant Negative Inhibition of the Type II cGMP-dependent Protein Kinase J. Biol. Chem., September 27, 2002; 277(40): 37242 - 37253. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. M. Gurnett, P. A. Liberator, P. M. Dulski, S. P. Salowe, R. G. K. Donald, J. W. Anderson, J. Wiltsie, C. A. Diaz, G. Harris, B. Chang, et al. Purification and Molecular Characterization of cGMP-dependent Protein Kinase from Apicomplexan Parasites. A NOVEL CHEMOTHERAPEUTIC TARGET J. Biol. Chem., May 3, 2002; 277(18): 15913 - 15922. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |